These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 16790944)
41. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Pina G; Dubois S; Murat A; Berger N; Niccoli P; Peix JL; Cohen R; Guillausseau C; Charrie A; Chabre O; Cornu C; Borson-Chazot F; Rohmer V; Clin Endocrinol (Oxf); 2013 Mar; 78(3):358-64. PubMed ID: 22913268 [TBL] [Abstract][Full Text] [Related]
42. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Scheuba C; Kaserer K; Weinhäusl A; Pandev R; Kaider A; Passler C; Prager G; Vierhapper H; Haas OA; Niederle B Surgery; 1999 Dec; 126(6):1089-95; discussion 1096. PubMed ID: 10598192 [TBL] [Abstract][Full Text] [Related]
43. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. Faggiano A; Milone F; Ramundo V; Chiofalo MG; Ventre I; Giannattasio R; Severino R; Lombardi G; Colao A; Pezzullo L J Clin Endocrinol Metab; 2010 Sep; 95(9):E32-6. PubMed ID: 20534767 [TBL] [Abstract][Full Text] [Related]
44. [Evaluation of an immunoassay for calcitonin]. Sylla Niang M; Lombardo F; Schlumberger M; Bidart JM Dakar Med; 2008; 53(1):76-83. PubMed ID: 19102121 [TBL] [Abstract][Full Text] [Related]
45. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse]. Łacka K; Michałek K; Majewski P Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567 [TBL] [Abstract][Full Text] [Related]
46. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Bieglmayer C; Scheuba C; Niederle B; Flores J; Vierhapper H Wien Klin Wochenschr; 2002 Apr; 114(7):267-73. PubMed ID: 12089862 [TBL] [Abstract][Full Text] [Related]
47. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Toledo SP; Lourenço DM; Santos MA; Tavares MR; Toledo RA; Correia-Deur JE Clinics (Sao Paulo); 2009; 64(7):699-706. PubMed ID: 19606248 [TBL] [Abstract][Full Text] [Related]
48. Long-term outcome of reoperations for medullary thyroid carcinoma. Fialkowski E; DeBenedetti M; Moley J World J Surg; 2008 May; 32(5):754-65. PubMed ID: 18188643 [TBL] [Abstract][Full Text] [Related]
49. Potential absence of prognostic implications of severe preoperative hypercalcitoninemia in medullary thyroid carcinoma. Zangeneh F; Gharib H; Goellner JR; Kao PC Endocr Pract; 2003; 9(4):284-9. PubMed ID: 14561572 [TBL] [Abstract][Full Text] [Related]
50. Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test". Niederle MB; Scheuba C; Gessl A; Li S; Koperek O; Bieglmayer C; Riss P; Selberherr A; Niederle B Biochem Med (Zagreb); 2018 Oct; 28(3):030710. PubMed ID: 30429678 [TBL] [Abstract][Full Text] [Related]
51. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Allelein S; Ehlers M; Morneau C; Schwartz K; Goretzki PE; Seppel T; Feldkamp J; Krieg A; Knoefel WT; Kuebart A; Haase M; Dringenberg T; Schmid C; Schott M Horm Metab Res; 2018 Jan; 50(1):23-28. PubMed ID: 29169190 [TBL] [Abstract][Full Text] [Related]